Detalles de la búsqueda
1.
Early antimicrobial prophylaxis in autologous stem cell transplant recipients: Conventional versus an absolute neutrophil count-driven approach.
Transpl Infect Dis
; 23(4): e13689, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34255395
2.
Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study.
Biol Blood Marrow Transplant
; 25(4): 699-711, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30423480
3.
Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors.
Haematologica
; 104(4): 844-854, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30381298
4.
Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial.
Biol Blood Marrow Transplant
; 24(11): 2216-2223, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30006305
5.
Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation.
Biol Blood Marrow Transplant
; 21(11): 1921-5, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26033279
6.
Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation.
Biol Blood Marrow Transplant
; 20(12): 1949-57, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25139216
7.
First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.
Biol Blood Marrow Transplant
; 18(8): 1150-63, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22510384
8.
Once daily busulfan cyclophosphamide is well tolerated and effective as a preparative regimen for allogeneic hematopoietic stem cell transplant.
J Oncol Pharm Pract
; 18(1): 17-22, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21228086
9.
Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease.
Biol Blood Marrow Transplant
; 17(1): 124-32, 2011 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-20601033
10.
Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.
Blood
; 113(21): 5074-82, 2009 May 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-19270260
11.
Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.
J Clin Oncol
; 35(36): 4003-4011, 2017 Dec 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-29040031
12.
Granulocyte colony-stimulating factor mobilizes more dendritic cell subsets than granulocyte-macrophage colony-stimulating factor with no polarization of dendritic cell subsets in normal donors.
Stem Cells
; 24(7): 1789-97, 2006 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-16822885
13.
Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease.
Biol Blood Marrow Transplant
; 11(3): 188-93, 2005 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-15744237
Resultados
1 -
13
de 13
1
Próxima >
>>